Fingerprint
Dive into the research topics of 'AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically